Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHOC | P08134 | 1/20 | 0.39 |
| ▸ | RHOA | P61586 | 1/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CPT1A | P50416 | 2/20 | 0.36 |
| ▸ | CPT2 | P23786 | 1/20 | 0.36 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.35 |
| ▸ | TRPC7 | Q9HCX4 | 1/20 | 0.35 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3584160 | 0.89 | RORC (0.38) | SMYD3ALDH1A1 | |
| SCHEMBL3582043 | 0.82 | CXCR3 (0.39) | — | |
| SCHEMBL3583398 | 0.81 | CNR2 (0.39) | SMYD3ALDH1A1 | |
| SCHEMBL13031558 | 0.80 | ALDH1A1 (0.38) | SMYD3ALDH1A1P2RY14MEN1KMT2A | |
| SCHEMBL3584366 | 0.78 | CXCR3 (0.50) | — | |
| SCHEMBL3587345 | 0.77 | GRIN2B (0.42) | CPT1ACPT2 | |
| SCHEMBL3581026 | 0.77 | GRIN2B (0.38) | CPT1ACPT2 | |
| SCHEMBL3583166 | 0.77 | GRIN2B (0.40) | CPT1ACPT2 | |
| SCHEMBL3590433 | 0.77 | TRPC3 (0.40) | ALDH1A1CPT1ACPT2KDM4ETRPC3 | |
| SCHEMBL3586581 | 0.76 | GAA (0.36) | CPT1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CXCR2 | RHOC 4155/4885RHOA 2822/4885SMYD3 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.